Tesla’s flailing sales figures have put the company closer to the red than it has been in years, according to financial results released Tuesday, threatening one of its biggest advantages over other EV players.The electric automaker reported $409 million in net income on $19.3 billion in revenue after delivering almost 337,000 EVs in the first quarter of the year. The company’s net income reflects a 71% drop from the same quarter last year. It was the worst quarter for Tesla deliveries in more than two year ...

NASHVILLE, Tenn., April 22, 2025 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) plans to release its first quarter 2025 financial results after the market closes on Tuesday, May 6, 2025. The Company also plans to discuss the results on a conference call scheduled for Wednesday, May 7, 2025, at 9:00 a.m. (ET).BROOKDALE SENIOR LIVING - EARNINGS CALLDate: Wednesday, May 7, 2025Time: 9:00 a.m. (ET) / 8:00 a.m. (CT)brookdaleinvestors.comCall Within US: +1 (800) 715-9871Call Outside US: +1 (646) 307-196 ...

PALM BEACH GARDENS, Fla., April 22, 2025 /PRNewswire/ -- Carrier Global Corporation (NYSE: CARR), global leader in intelligent climate and energy solutions, will release its first quarter 2025 earnings on Thursday, May 1, 2025 and host a conference call and webcast at 7:30 a.m. ET.The webcast and presentation will be available at ir.carrier.com. To listen to the earnings call by phone, participants must pre-register at the following link: Carrier Earnings Call Registration. All registrants will receive dial ...

DUBLIN, April 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 first quarter financial results on Tuesday, May 6, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2025 first quarter financial results and provide a business and financial update.  Audio webcast/conference call:U.S. Dial-In Number: +1 800 715 9871Ireland Dial-In Number: +353 1800 943 926A ...

Core Insights - SAP's Q1 2025 results demonstrate strong financial performance, with total revenue increasing by 12% to €9.01 billion, driven by a 27% rise in cloud revenue [4][5][8] - The current cloud backlog reached €18.2 billion, reflecting a growth of 28% year-over-year, indicating robust demand for SAP's cloud solutions [5][7] - The company maintains a resilient business model with 86% of revenue being more predictable, showcasing stability in uncertain market conditions [2][8] Financial Performance - SaaS/PaaS revenue grew by 30% to €4.89 billion, with Cloud ERP Suite revenue up 34% to €4.25 billion [4][5] - Operating profit surged to €2.33 billion, a significant increase from a loss of €787 million in Q1 2024, highlighting effective cost management and operational efficiencies [4][10] - Basic earnings per share rose to €1.52, compared to a loss of €0.71 in the previous year, reflecting improved profitability [11] Cash Flow and Share Repurchase - Operating cash flow increased by 31% to €3.78 billion, while free cash flow rose by 36% to €3.58 billion, driven by higher profitability [12] - As of March 31, 2025, SAP repurchased shares worth approximately €3.1 billion under its €5 billion share repurchase program [13] Strategic Initiatives - The 2024 Transformation Program aimed at enhancing operational scalability and strategic growth areas concluded successfully, with total expenses of approximately €3.2 billion [14] - SAP's "RISE with SAP" initiative continues to attract global customers, indicating strong market acceptance of its cloud solutions [15][18] Market Outlook - SAP anticipates a slight deceleration in current cloud backlog growth for 2025, reflecting the dynamic and uncertain market environment [21] - The company projects cloud revenue growth at constant currencies to be between 26% to 28% for 2025, indicating continued optimism despite market challenges [23]

Company Overview - Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing therapeutic innovations to improve medical care [3] - The company utilizes advanced science, patented technologies, and an innovative approach to drug discovery and development [3] - Heron aims to advance the standard-of-care for acute care and oncology patients through its portfolio of products [3] Upcoming Events - The company will host a conference call and live webcast on May 6, 2025, at 8:00 a.m. ET to report first quarter 2025 financial results and discuss recent business highlights [1] - Participants can access the conference call via a registration link and are encouraged to join fifteen minutes early to avoid delays [2] - An archive of the teleconference and webcast will be available on Heron's website for 60 days following the call [2]

Group 1 - Compass, Inc. is the largest residential real estate brokerage in the United States by sales volume, as ranked by Real Trends for the fourth consecutive year in April 2025 [1][3] - The company will release its first quarter 2025 financial results after market close on May 8, 2025, followed by a conference call and webcast at 5:00 p.m. ET [1] - Compass provides a tech-enabled platform that supports residential real estate agents with cloud-based software for various functions, enhancing efficiency and service delivery [1] Group 2 - The Compass network includes Christie's International Real Estate, which has over 100 independently owned brokerage affiliates in 50 countries and territories [1] - Investors are encouraged to monitor Compass' Investor Relations website for important disclosures and updates [2] - An audio recording of the upcoming conference call will be available for replay for 90 days after the event [3]

Core Insights - Genpact has been recognized as a Leader in NelsonHall's 2025 NEAT evaluation for P&C Operations: Analytics & AI, showcasing its advanced technology leadership in driving innovation and efficiency in the property and casualty insurance sector [1][4]. Group 1: Recognition and Evaluation - Genpact is named a Leader in all six evaluation categories of NelsonHall's NEAT assessment, which includes overall, underwriting, customer service/administration, claims administration, operations analytics, and AI/GenAI [2][3][4]. - The NEAT assessment evaluates vendors based on their ability to deliver immediate impact and future-ready solutions, reflecting Genpact's commitment to innovation and measurable impact across the P&C insurance value chain [4]. Group 2: AI and Technology Integration - Genpact's AI-first approach provides actionable insights that enhance efficiency and create long-term value for clients by embedding AI, data, and technology into underwriting, claims management, and operations [5][6]. - The company supports over 160 insurers globally, offering end-to-end solutions such as underwriting modernization and AI-powered claims management, bolstered by strategic investments in AI and partnerships with industry leaders [5][6]. Group 3: Key Offerings - Key offerings for P&C insurers include the Genpact Underwriting Manager, Genpact Claims Manager, Genpact AI Adjuster Assist, and Catastrophe Claims Management, which automate and streamline various processes within the insurance value chain [9].

Core Viewpoint - Rocket Lab USA, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors regarding the launch timeline and reliability of its Neutron rocket [1][3][4]. Group 1: Allegations and Impact - The lawsuit alleges that Rocket Lab delayed plans for three barge landing tests and that a critical potable water issue would not be resolved until January 2026, impacting the launch pad preparation [3]. - It is claimed that these issues pose a substantial risk to the mid-2025 launch of the Neutron rocket, which has only one contract at a discount with an unreliable partner [3]. - Following a report from Bleecker Street Research on February 25, 2025, which suggested Rocket Lab misled investors about the Neutron rocket's launch likelihood, the company's stock price fell nearly 10% [4]. Group 2: Legal Process and Representation - Investors who purchased Rocket Lab securities during the specified class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [5]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [5]. Group 3: Company Background - Rocket Lab is a space company that provides launch services and space systems solutions for the space and defense industries [2].

Although Applied Materials (AMAT 2.03%) stock wasn't doing badly in late-session trading on Tuesday, there were plenty of other titles that were eclipsing it. Its rise was tempered by an analyst's price target cut, which dampened sentiment on the chipmaking equipment specialist's prospects.With that moderate headwind, Applied Materials was rising by 1.7% on the day; meanwhile, the S&P 500 index was clocking a 2.3% increase.A $30-per-share chopThat morning, Tom O'Malley of storied bank Barclays reduced his A ...